News
-
Cambridge Healthcare Innovations announced that its Quattrii blister-based DPI has been selected for delivery of inhaled dry powder formulations of biologics being developed by University College London professor Jenny Lam. CHI partnered with Aptar in… Read more . . .
-
1nhaler raises additional £2.2 million for development of its single-dose salbutamol (albuterol) DPI
1nhaler announced that it has closed a £2.2 million funding round led by Archangels, with the proceeds intended to support preparations for a clinical trial of its disposable, single-dose 1nhaler Salbutamol DPI with a goal… Read more . . .
-
Tiziana Life Sciences has announced that the Phase 2a INFORM-MS study of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis met both of its primary endpoints, demonstrating significant reduction in microglial activation at Week… Read more . . .
-
Merck has announced the initiation of the Phase 3 ENHANCE-3 study of Ohtuvarye ensifentrine inhalation suspension, which is expected to enroll 2,136 COPD patients and will evaluate Ohtuvarye for the prevention of exacerbations. Merck acquired… Read more . . .
-
Following soon after United Therapeutics’ announcement that the FDA had cleared an IND for a Phase 2 trial of the company’s treprostinil SMI in patients with PH-COPD, the company has announced an IND clearance for… Read more . . .
-
Phase 2a trial of AerTherapeutics’ nebulized fexlamose failed to meet primary or secondary endpoints
Aer Therapeutics has announced that a Phase 2a trial of fexlamose (AER-01) inhalation solution in patients with moderate-to-severe COPD failed to meet primary or secondary endpoints and also demonstrated an increased incidence of adverse events… Read more . . .
-
Blue Lake Biotechnology announced that it has received a $5 million grant from the Gates Foundation to support the addition of younger children to a Phase 1/2a clinical trial of its BLB201 nasal vaccine against… Read more . . .
-
This year’s Drug Delivery to the Lungs (DDL) meeting will introduce a few innovations to its regular program of scientific lectures, industry and poster exhibitions, including the new DDL Incubator. DDL 2026 will take place… Read more . . .
-
Aptar Pharma announced that it has acquired Pulmotree, the developer of the Kolibri mesh nebulizer, which it refers to as a non-propellant liquid inhaler. The Kolibri nebulizer is a breath-activated, connected device that provides real-time… Read more . . .
-
AptarGroup has announced that Virginie Maes, who is currently VP of Healthcare Flexibles at Amcor, will join the company as President of Aptar Pharma as of January 1, 2027. Maes joined Amcor in 2016; her prior… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here

